To optimize stratification of patients according to MFAP4 serum level, we determined rule‐in and rule‐out cut‐offs for advanced fibrosis and cirrhosis by setting specificity (to rule‐in) or sensitivity (to rule‐out) to 90%. This evidence concerns the gene MFAP4 and Cirrhosis.